XML 24 R14.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Related Party Transactions | 9 Months Ended
--- | ---
Sep. 30, 2018
Related Party Transactions [Abstract] |
Related Party Transactions |
7. | Related Party Transactions
Astellas is an equity investor in the Company and considered a related party. The Company recorded revenue related to collaboration agreements with Astellas of $5.1 million and $5.3 million during the three months ended September 30, 2018 and 2017, respectively, and $30.8 million and $15.1 million during the nine months ended September 30, 2018 and 2017, respectively. The related party revenue for the nine months ended September 30, 2018 included $14.9 million of a $15.0 million regulatory milestone under the Japan Agreement that was included in the transaction price during the second quarter of 2018. See Note 2 and below for details. The related party revenue was recast for the three and nine months ended September 30, 2017 as a result of adoption of the new revenue standards. See Note 1 for details. The Company recorded expense related to collaboration agreements with Astellas of $0.4 million and $0.2 million during the three months ended September 30, 2018 and 2017, respectively, and $1.1 million and $0.8 million during the nine months ended September 30, 2018 and 2017, respectively. As of September 30, 2018 and December 31, 2017, accounts receivable from Astellas were $19.4 million and $4.0 million, respectively, and amounts due to Astellas were $0.4 million and $0.3 million, respectively. The accounts receivable from Astellas as of June 30, 2018 included $20.9 million related to a sale of roxadustat API to Astellas during the second quarter of 2018, which was received during the three months ended September 30, 2018. The sale was made pursuant to a material transfer agreement in anticipation of the execution of an amendment to the Japan Agreement allowing Astellas to manufacture roxadustat drug product, which is expected to be finalized in the fourth quarter of 2018. The sale enables Astellas to conduct the commercial scale manufacturing validation for roxadustat drug product in anticipation of commercial launch in Japan. The associated consideration was recorded as deferred revenue because Astellas’ right to use the material was limited as of September 30, 2018.

X
- References No definition available. + Details
Name: | us-gaap_RelatedPartyTransactionsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -URI http://asc.fasb.org/topic&trid=2122745 + Details
Name: | us-gaap_RelatedPartyTransactionsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration